Killer antibodies against AML, press conference EHA 2016
June 11, 2016
Dr Hazenberg presents, at a press conference at EHA 2016, details of our work about the discovery of antibodies that bind specifically to AML cells from patients who are in remission from AML. Watch the presentation here and an interview with Dr Hazenberg about the work here.
Press release European Hematology Association, Copenhagen, June 11, 2016
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia. Working with patients who are in remission from AML, we discovered antibodies that bind specifically to AML cells. We suspect that these antibodies have general utility in treating other patients with AML. The target of these antibodies was unanticipated: the U5 snRNP200 protein complex, normally expressed in the cell cytoplasm and nucleus but expressed on the outer surface of AML cells. Moreover, we found that U5 specific antibodies are ‘killer antibodies’: they kill AML blasts in vitro and (in a mouse model) in vivo. We are now advancing these antibodies through early development with the goal of initiating human clinical trials in the near future. (see also infographic (dutch) here).